Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.
In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
In this video, Dr. Edward Kim provides details on the TAPUR trial, which uses broad genomic test results to aid in precision medicine for cancer patients.
Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
A recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.
When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
Dr. Bobby Lazzara highlights a recent study published in JAMA Oncology on ethnic/racial disparity in genome sequencing and how researchers may be leaving this population behind.
The University of Illinois at Chicago, Northwestern University, the University of Chicago, and other affiliated hospitals and clinics have been selected to enroll 150,000 Illinoisans in the national Precision Medicine Initiative Cohort Program.